{"id":"vgr-r01","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This leads to a decrease in angiotensin II levels, resulting in vasodilation and reduced blood pressure.","oneSentence":"VGR-R01 is a small molecule drug that targets the renin-angiotensin system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:33.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05694598","phase":"PHASE1","title":"Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2023-03-27","conditions":"Bietti Crystalline Dystrophy","enrollment":12},{"nctId":"NCT06699108","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2024-12-13","conditions":"Bietti Crystalline Dystrophy, Inherited Retinal Diseases","enrollment":45},{"nctId":"NCT05399069","phase":"EARLY_PHASE1","title":"Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2022-09-15","conditions":"Bietti Crystalline Dystrophy","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VGR-R01","genericName":"VGR-R01","companyName":"Shanghai Vitalgen BioPharma Co., Ltd.","companyId":"shanghai-vitalgen-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VGR-R01 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}